Lilly, Boehringer say diabetes drug meets goals in later trials

(Reuters) - Eli Lilly and Co and Boehringer Ingelheim said on Monday that a treatment for type 2 diabetes, empagliflozin, had been shown to work in four late-stage trials.

homeschooling in arizona school field trips saxon geometry